Endometrial Cancer — Clinical

A 58-year-old postmenopausal woman from Delhi presents with vaginal bleeding for 3 months. She is obese (BMI 34 kg/m²), hypertensive, and diabetic. On examination, the uterus is normal size and mobile. Pap smear is normal. Transvaginal ultrasound shows an endometrial thickness of 18 mm with a heterogeneous echo pattern. Endometrial biopsy reveals well-differentiated adenocarcinoma with invasion into the inner half of the myometrium. MRI pelvis confirms no cervical or parametrial involvement. What is the most appropriate next step in management?

A 62-year-old woman with type 2 diabetes and obesity undergoes diagnostic hysteroscopy for postmenopausal bleeding. Histopathology reveals Grade 1 endometrioid adenocarcinoma, confined to the inner half of the myometrium on curettage. MRI shows no extrauterine disease. What is the most appropriate next step in management?

A 52-year-old Indian woman with obesity and type 2 diabetes presents with postmenopausal bleeding. Endometrial cancer is suspected. Which clinical or pathological feature best distinguishes early-stage Type I endometrial cancer (favorable prognosis) from early-stage Type II endometrial cancer (poor prognosis)?

A 58-year-old postmenopausal woman presents with abnormal uterine bleeding. Endometrial biopsy reveals grade 1 endometrioid adenocarcinoma confined to the endometrium (stage IA). She is medically fit and undergoes total abdominal hysterectomy with bilateral salpingo-oophorectomy. Histopathology confirms no myometrial invasion, no lymphovascular space invasion, and negative pelvic lymph nodes. What is the drug of choice for adjuvant chemotherapy in this patient?

A 65-year-old woman with a BMI of 38 kg/m² and history of type 2 diabetes presents with abnormal uterine bleeding. Endometrial biopsy confirms grade 3 endometrioid adenocarcinoma with deep myometrial invasion (>50%) and lymphovascular space invasion. Staging CT shows no distant metastases. She undergoes total abdominal hysterectomy with bilateral salpingo-oophorectomy and pelvic lymphadenectomy. Pelvic lymph nodes are negative. What is the drug of choice for adjuvant treatment in this patient?